UNSPSC 51284134: Cefodizime sodium

This classification denotes a beta-lactam antibacterial with the molecular formula C20H18N6O7S4.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (z)-7-(2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-(5-carboxymethyl-4-methylthiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid, disodium salt, but more generally known as cefodizime sodium, which bears US NIH Compound Identifier 9576734.

UNSPSC 51284134 Cefodizime sodium is a Commodity code that nominally denotes a specific injectable antibiotic, but recent state and local procurement activity tagged under this code shows little substantive alignment with the product itself. The available solicitation records—an Illinois Department of Public Health piggyback pharmaceutical award and a Seminole County, Florida naloxone and drug deactivation systems procurement—do not reference cefodizime sodium at all. Instead, they document pharmaceutical supply contracts for unrelated products (doxycycline, ciprofloxacin, and naloxone), suggesting that state and local jurisdictions may be mistagging broader pharmaceutical procurement under a narrowly defined commodity code rather than sourcing cefodizime specifically.

Geographic activity shows Illinois and Florida as recent posting locations, though both opportunities involve pharmaceutical or medical supply sourcing rather than cefodizime procurement itself. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 via an Invitation for Bid process, while Seminole County released an Invitation for Bid on June 30, 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (note: the due date in the record predates the posting date, indicating a data anomaly). The code shows minimal recent relevant activity tied directly to cefodizime sodium procurement.